Chugai to deploy Biomni Lab for drug discovery using its research data

Chugai to deploy Biomni Lab for drug discovery using its research data

On August 4, Phylo and the Japanese pharmaceutical company Chugai announced a collaboration. The agentic system will operate within Chugai's secure environment and use the company's research data. Chugai identified four applications: single-cell analysis, human genetics, disease biology, and drug target assessment.

When a team searches for a drug target, meaning a protein or another component of a disease that a molecule is intended to affect, a scientist compares experimental results, genetic data, and published research. The scientist then develops a hypothesis and decides what the next experiment should test.

Biomni Lab is intended to support this work by connecting Chugai's internal data with biomedical databases and analytical tools. In their paper on Biomni, the authors described the platform as a language model that finds material for a research plan and executes code for various biomedical tasks.

This is not access to a chatbot. It is the integration of a system into workflows that use a pharmaceutical company's proprietary data. Phylo expects the system to help researchers substantiate hypotheses and choose the next step. At Chugai, these decisions will involve cell analysis, genetics, disease biology, and the identification of drug targets.

On July 28, Ono Pharmaceutical connected Biomni Lab to its experimental history, internal data, experimental design, and computational biology workflows. Chugai became the second publicly named pharmaceutical company to announce that it would deploy Biomni Lab in drug discovery. Both agreements address the same practical task: connecting data and analysis to the decision about which biological question to test next.